Heron Therapeutics, Inc. (NASDAQ: HRTX ) has four approved therapeutics, bringing in net product sales of $39M in Q1'25 between them, but the company believes one of the four drugs (Zynrelef) could be a $100M+ drug annually. I rated HRTX a buy in AprilScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst ...

For the quarter ended March 2025, Heron Therapeutics (HRTX) reported revenue of $38.9 million, up 12.2% over the same period last year. EPS came in at $0.01, compared to -$0.02 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $37.08 million, representing a surprise of +4.93%. The company delivered an EPS surprise of +200.00%, with the consensus EPS estimate being -$0.01.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wa ...

Heron Therapeutics (HRTX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.03 per share when it actually produced earnings of $0.02, delivering a surprise of 166.67%.Over the last four q ...

Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call May 06, 2025 08:00 AM ET Company Participants Melissa Jarel - Executive Director - LegalCraig Collard - CEO & DirectorIra Duarte - Executive VP & CFOClara Dong - Vice President - Biotechnology Equity ResearchCarl Byrnes - Managing Director Conference Call Participants Serge Belanger - Senior Analyst Operator Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 twenty twenty five Conference Call. At this time, all participants are i ...

业绩总结 - 2025年第一季度净收入为260万美元，较2024年同期的316万美元亏损有所改善[7] - 2025年第一季度净收入为3890万美元，较2024年同期的3467万美元增长了12.3%[29] - 2025年第一季度调整后EBITDA为620万美元，较2024年同期的亏损73万美元显著改善[30] - 2025年第一季度总运营费用为2729万美元，较2024年同期的3102万美元下降了11.5%[29] 用户数据 - 2025年第一季度肿瘤护理业务净销售额为2860万美元[10] - 2025年第一季度CINVANTI®净销售额为2570万美元，较2024年同期增长0.5%[11] - 2025年第一季度APONVIE®净销售额为830万美元，较2024年同期增长432%[18] - 2025年第一季度ZYNRELEF®净销售额为800万美元，较2024年同期增长60%[18] 未来展望 - 2025年产品收入指导范围为1.53亿至1.63亿美元[32] - 调整后EBITDA指导范围为400万至1200万美元[32] 现金流状况 - 2025年现金及短期投资余额为5067万美元，较2024年同期的5928万美元下降了14.1%[29]

Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call May 06, 2025 08:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 twenty twenty five Conference Call. At this time, all participants are in a listen only mode. Please be advised that today's conference is being recorded. After the speakers' presentation, there will be a question and answer session. To ask a question, please press 11 on your telephone I would now like to hand the conference over to your speaker ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (Address of principal executive of ...

Exhibit 99.1 Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates CARY, May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates. "We are off to a strong start in 2025, achieving record adjusted EBITDA for the first quarter. Building on our efforts to strength ...

Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 2032 Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today anno ...

— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 —CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related t ...